Adenovirus armed with bispecific t cell engager (bite)
AssigneePsioxus Therapeutics Limited
InventorsBrian Robert CHAMPION, Alice Claire Noel BROMLEY, Joshua David FREEDMAN, Kerry David FISHER, Leonard William SEYMOUR
Life of this patent
Estimating the term…
Abstract
A modified adenovirus, in particular Enadenotucirev (EnAd), armed with a bispecific T cell engager (BiTE™) comprising at least two binding domains, wherein at least one of the domains is specific for a surface antigen on a T-cell of interest. Also provided are a composition, such as a pharmaceutical formulation comprising the virus, use of the virus and virus formulations for treatment, such as in the treatment of cancer. The disclosure also extends to processes for preparing the virus.
Claims47
An adenovirus comprising a sequence of formula (I):
- 5′ITR-B1-BA-B2-BX-BB-BY-B3-3′ITR (I)
- wherein:
- B1 is bond or comprises:
- E1A, E1B or E1A-E1B;
- BA comprises-E2B-L1-L2-L3-E2A-L4;
- B2 is a bond or comprises:
- E3;
- BX is a bond or a DNA sequence comprising:
- a restriction site, one or more transgenes or both;
- BB comprises L5;
- BY is a bond or a DNA sequence comprising:
- a restriction site, one or more transgenes or both;
- B3 is a bond or comprises:
- E4;
- wherein the adenovirus encodes a Bispecific T cell Engager (BiTE) comprising at least two binding domains wherein at least one of the said domains is specific to a surface antigen on an immune cells of interest, such as a T cell of interest;
- and
- wherein the adenovirus is EnAd or Ad11.
Dependencies are inferred from the claim text.